Xintela develops groundbreaking stem cell therapies and targeted cancer therapies for diseases that lack effective treatment
XSTEM® - innovative stem cell platform for future medicines
Xintela’s research and development in stem cell therapy is blazing a new path for the treatment of severe diseases such as osteoarthritis and difficult-to-heal wounds.
Xintela’s development of innovative treatments in stem cell therapy is based on our patented biomarker technology that we use to manufacture stem cell products with highly competitive therapeutic efficacy, for both humans and animals. Our clinical study on knee osteoarthritis has shown that XSTEM® has disease-modifying properties, which gives Xintela a strong position in the continued development and commercialization of our stem cell products for the global life science market.
XSTEM® for knee osteoarthritis
Our clinical phase I/IIa study in knee osteoarthritis has shown that XSTEM® reduces pain in the knee joint and improves joint function and cartilage and bone structure.
XSTEM® for difficult-to-heal wounds
Our clinical phase I/IIa study with XSTEM® on difficult-to-heal venous leg ulcers has been completed and the evaluation of the results is ongoing.
XSTEM® for ARDS treatment
Our preclinical study on Acute Respiratory Distress Syndrome (ARDS) has shown that XSTEM® reduces blood coagulation and damage to lung tissue.
EQSTEM® for Equine Joint Disease
Xintela has entered into a collaboration and license agreement for the clinical development and commercialization of the stem cell product EQSTEM® for horses.
- Latest News
- Financial Reports
